Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07397338 · ClinicalTrials.gov registry record · Phase 1

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

A Phase 1 study of Advanced Solid Tumors and NSCLC, sponsored by Revolution Medicines.

Recruiting
Registry status
Phase 1
Development phase
370
Enrollment target
1
Study location

NCT07397338 is a Phase 1 study of Advanced Solid Tumors and NSCLC that is actively recruiting participants, run by Revolution Medicines. The registered enrollment target is 370 participants, above the 196-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (89% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07397338, a Phase 1 study of Advanced Solid Tumors and NSCLC, is actively recruiting participants, sponsored by Revolution Medicines.

RECRUITING
Registry status
Phase 1
Development phase
370 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors with a RAS mutation.

Conditions Studied

Advanced Solid Tumors NSCLC Non-small Cell Lung Cancer (NSCLC) Metastatic Solid Tumors Colorectal Cancer (CRC) CRC

Interventions

  • DRUG Ivonescimab
  • DRUG Elironrasib
  • DRUG Daraxonrasib
  • DRUG Zoldonrasib
  • DRUG Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only)

Study Locations (1)

Virginia

  • NEXT Virginia - Fairfax

Trial Details

FieldValue
Enrollment Target 370 participants
Start Date 2026-01-30
Est. Completion 2029-05
Phase Phase 1

Sponsor

Revolution Medicines

16 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07397338

The ClinicalTrials.gov registry entry for NCT07397338 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 370 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 196-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (89% higher). The listed sponsor is Revolution Medicines, which has 16 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Advanced Solid Tumors appearing as the primary indexed condition, and to 5 interventions - of which Ivonescimab is the first listed.

NCT07397338 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.

Frequently Asked Questions

What is clinical trial NCT07397338 about?

NCT07397338 is a clinical study titled "Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors with a RAS mutation.

What is the current status of trial NCT07397338?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 370 participants. The study started on 2026-01-30. Estimated completion is 2029-05.

What conditions does trial NCT07397338 study?

This clinical trial studies the following conditions: Advanced Solid Tumors, NSCLC, Non-small Cell Lung Cancer (NSCLC), Metastatic Solid Tumors, Colorectal Cancer (CRC).

What interventions are being tested in trial NCT07397338?

The interventions under investigation include: Ivonescimab (DRUG), Elironrasib (DRUG), Daraxonrasib (DRUG), Zoldonrasib (DRUG), Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only) (DRUG).

Who is sponsoring clinical trial NCT07397338?

This trial is sponsored by Revolution Medicines, which has 16 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07397338 being conducted?

This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

NSCLC

All registered trials for this condition

Virginia

All trials with a study site in Virginia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.